

Hyperbilirubinemia in the Neonate

Jill Herring, APRN

Ilana Waynik, MD

Mary Lussier, RN, IBCLC

Kristin Welch, MD



What is a Clinical Pathway?



An evidence-based guideline that decreases unnecessary variation and helps promote safe, effective, and consistent patient care.

Objectives of Pathway



- To decrease variation in the care of neonates admitted for hyperbilirubinemia
- To triage admission processes including when to directly admit to medical/surgical floors vs. Neonatal Intensive Care Unit
- To standardize breastfeeding support during admission, including pumping, when to supplement, and lactation consultation for all breastfeeding infants
- To encourage continuation of exclusive breastfeeding
- To decrease unnecessary use of intravenous therapies
- To guide care involving phototherapy, and decrease delay in initiation of phototherapy
- To standardize laboratory monitoring and decrease unnecessary rebound total serum bilirubin testing
- To ensure Vitamin D supplementation, when indicated

Why is Pathway Necessary?



- Neonates requiring readmission for treatment of hyperbilirubinemia patients are a vulnerable low volume though high risk population
- In 2022 the APP released updates from the original 2004 guidelines for the care of infants ≥ 35 weeks gestation
- Primary goal of care is the prevention of kernicterus; a permanent disabling neurological condition
- Reducing variation in care such as feeding support, laboratory assessments, and phototherapy treatment is essential to providing high value and equitable care for this vulnerable population
- Maximizing nutrition and initiating lactation support at the start of the admission are essential parts of care often overlooked for these patients

Updates to Pathway 2023



- Page 1 of pathway is a navigation page for quick clicking to admission algorithm, ED management, inpatient management, and helpful appendices
- Updated bilirubin nomograms and treatment criteria based upon updated APP clinical practice guideline released August 2022
- Clarified recommendations for extended lab evaluation and when it is indicated
- Improved guidance for Total Serum Bilirubin (TSB) monitoring during and after phototherapy
- Appendix C Etiologies and Risk Factors updated
- Defined phototherapy dosing to ensure patient receives intensive phototherapy
- Improved guidance for expected feeding volumes of a neonate based on age (Inpatient algorithm and appendix D) and how to assess for suboptimal intake (appendix D)

What is Neonatal (Indirect) Hyperbilirubinemia




- More than 80% of neonates will have some degree of jaundice
- Neonatal Hyperbilirubinemia is nearly a universal condition in the newborn
- Clinical Manifestations
 - yellowing of skin, sclera, mucous membranes (jaundice)
- Biochemical Manifestations
 - Increased total serum bilirubin (TSB) as a result of an elevated indirect serum bilirubin
- Requires a consistent approach to screening and treatment
- The mainstay of treatment is NUTRITION and PHOTOTHERAPY (when indicated)



Kemper, A. R., et al. (2022).
Gallois, Sarathy, & Staude (2022)

Bilirubin Metabolism

PRODUCTION



What's the big deal?



- Bilirubin is a cell toxin
- High free unconjugated bilirubin can be deposited in the tissues, including the brain
- Bilirubin neurotoxicity and kernicterus are preventable consequences brain damage caused by bilirubin deposition in the brain

This is the Hyperbilirubinemia in the Neonate Clinical Pathway – Navigation page

Navigation page provides quick clicking to admission algorithm, ED management, inpatient management, and helpful appendices

We will be reviewing each component of the pathway in the following slides.



Inclusion criteria: newborns already discharged from birth hospital or who remain in NICU AND are ≤ 14 days old, born at ≥ 35 wk gestation, previously suspected/known indirect hyperbilirubinemia with suspected/known need for phototherapy

Exclusion Criteria: >14 days old; <35 wk gestation at birth, suspected sepsis, signs of hyperbilirubinemia neurotoxicity (hypertonia, arching, retrocollis, opisthotonos, fever, high pitched cry)

Phase of Care Navigation Links

- [Admission Algorithm](#)
- [Emergency Department](#)
- [Inpatient Management](#)

Appendices and Feeding Log

- [Appendix A: Phototherapy Nomograms](#)
- [Appendix B: Exchange Transfusion Nomograms](#)
- [Appendix C: Etiologies and Risk Factors](#)
- [Appendix D: Admitting RN Tips and Tricks](#)
- [Appendix E: Feeding Log](#)

NEXT PAGE



Hyperbilirubinemia in the Neonate Clinical Pathway

Please review these updated inclusion and exclusion criteria:

- Newborns already discharged from birth hospital or who remain in NICU AND ...rest of criteria remain the same

Inclusion criteria: newborns already discharged from birth hospital or who remain in NICU AND are ≤ 14 days old, born at ≥ 35 wk gestation, previously suspected/known indirect hyperbilirubinemia with suspected/known need for phototherapy

Exclusion Criteria: >14 days old; <35 wk gestation at birth, suspected sepsis, signs of hyperbilirubinemia neurotoxicity (hypertonia, arching, retrocollis, opisthotonos, fever, high pitched cry)

Phase of Care Navigation Links

- [Admission Algorithm](#)
- [Emergency Department](#)
- [Inpatient Management](#)

Appendices and Feeding Log

- [Appendix A: Phototherapy Nomograms](#)
- [Appendix B: Exchange Transfusion Nomograms](#)
- [Appendix C: Etiologies and Risk Factors](#)
- [Appendix D: Admitting RN Tips and Tricks](#)
- [Appendix E: Feeding Log](#)

Inclusion criteria: newborns already discharged from birth hospital or who remain in NICU AND are ≤ 14 days old, born at ≥ 35 wk gestation, previously suspected/known indirect hyperbilirubinemia with suspected/known need for phototherapy


Exclusion Criteria: >14 days old; <35 wk gestation at birth, suspected sepsis, signs of hyperbilirubinemia neurotoxicity (hypertonia, arching, retrocollis, opisthotonos, fever, high pitched cry)

NEXT PAGE



This is the Hyperbilirubinemia in the Neonate Clinical Pathway. – Admission Algorithm

- Admission algorithm helps determine if patient requires admission, and if may be direct admission to med/surg vs. requires ED visit vs. requires direct admission to NICU
 - Many patients can avoid the ED and be directly admitted!
- Admission criteria are based on updated bilirubin nomograms and patient's risk for hemolysis.
- Links added to bring you directly to nomograms and bilitool.org to assist with assessment for treatment based on updated nomograms
- Gestational age is accounted for in each nomogram (no risk factors & 1 or more risk factors)



¹Signs of Hyperbilirubinemia Neurotoxicity

- Hypertonia
- Archling
- Retrocollis
- Opisthotonos
- Fever
- High pitched cry


²Direct admission criteria:

- Patient has TSB within 8 hours of admission
- Patient seen in last 24 hours by referring service
- Patient has accepting attending
- Patient stable to be on med/surg unit without medical attention for 30 minutes


RETURN TO THE BEGINNING

Phototherapy Nomograms

Phototherapy Thresholds: **No** Hyperbili Neurotoxicity Risk Factors



Phototherapy Thresholds: **One or More** Hyperbili Neurotoxicity Risk Factors




Hyperbilirubinemia Neurotoxicity Risk Factors:

Albumin <3.0 g/dL; isoimmune hemolytic disease, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or other hemolytic conditions; sepsis; or any significant clinical instability in the previous 24 hours. Gestational age accounted for within in nomogram.


Adapted from: Kemper, A. R., et al. (2022). Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. *Pediatrics*, 150(3), e2022058859.

Exchange Transfusion Nomograms

Exchange Transfusion Thresholds: **No** Hyperbili Neurotoxicity Risk Factors



Exchange Transfusion Thresholds: **One or More** Hyperbili Neurotoxicity Risk Factors



Hyperbilirubinemia Neurotoxicity Risk Factors:

Albumin <3.0 g/dL; isoimmune hemolytic disease, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or other hemolytic conditions; sepsis; or any significant clinical instability in the previous 24 hours. Gestational age accounted for within in nomogram.


Adapted from: Kemper, A. R., et al. (2022). Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. *Pediatrics*, 150(3), e2022058859.

CLINICAL PATHWAY: Hyperbilirubinemia Emergency Room Management

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

This is the Hyperbilirubinemia in the Neonate Clinical Pathway. – Emergency Room Management

We will be reviewing each component in the following slides.



RETURN TO THE BEGINNING

CONTACTS: JILL HERRING, APRN | MARY LUSSIER, RN, IBCLC | ILANA WAYNIK, MD | KRISTIN WELCH, MD

LAST UPDATED: 02/27/23

©2019 Connecticut Children's Medical Center. All rights reserved.



Hyperbilirubinemia in the Neonate Clinical Pathway. –Emergency Management

Delay in initiation of phototherapy must be avoided

- ED RN to obtain total and direct serum bilirubin & POCT glucose by heel stick upon rooming
- Start patient on **biliblanket STAT** while labs are pending

Inclusion criteria: newborns already discharged from birth hospital or who remain in NICU **AND** are ≤14 days old, born at ≥35 wk gestation, previously suspected/known indirect hyperbilirubinemia with suspected/known need for phototherapy
Exclusion Criteria: >14 days old; <35 wk gestation at birth, suspected sepsis, signs of hyperbilirubinemia neurotoxicity

Determine appropriate admission service (MS Floor vs NICU) based on outpatient bilirubin [Admission Algorithm]:

- **Triage RN:** ESI level 2 (acute)
- **ED RN:**
 - Obtain sample for total and direct serum bilirubin and POCT glucose via heel stick, regardless of need for additional labs or IV access (includes patients w/prior result < 8 hrs old)
 - Place infant on bili blanket STAT

- Signs of Hyperbilirubinemia Neurotoxicity:
- Hypertonia
 - Arching
 - Retrocollis
 - Opisthotonos
 - Fever
 - High pitched cry

Initial Provider Assessment

Clinical history/physical exam:

- Gestational Age
- Current age in hours
- Mother's blood type (infant's blood type if mother type O, Rh negative, or antibody +)
- Birth weight and current weight
- Method and frequency of feeding
- Stool and urine output
- Signs/level of dehydration

Hyperbilirubinemia Evaluation for Treatment:


- Consider etiologies and risk factors for neonatal hyperbilirubinemia (Appendix C)
- Determine if there is pathologic rate of rise (≥ 0.2mg/dl/hour or > 5mg/dl in 24 hours)
- Determine threshold for phototherapy and exchange transfusion using **BiITool** or **Phototherapy Nomograms (Appendix A)** and **Exchange Transfusion Nomograms (Appendix B)**

Laboratory: Consider additional labs as clinically indicated

- **CBC w diff, reticulocyte count, DAT, (if not known), type and screen, peripheral smear** - If mother/baby blood types unknown, early-onset jaundice (first 24 hrs after birth), phototoxic or exchange transfusion during birth hospitalization, bilirubin levels w/in 2 mg/dL of threshold in 1st 48 hrs of life, rapidly rising TSB levels (increasing by ≥0.2 mg/dL per hour), ABO incompatibility regardless of DAT result, family hx inherited hemolytic disorder
- **G6PD** - If clinical concern for hemolysis and DAT negative, or if early onset hyperbili and persistent beyond first week of life, familial or racial/ethnic risk
- **Electrolytes, POCT urine dip for specific gravity** - Obtain if concern for moderate or severe dehydration
- Additional labs considerations (if clinically indicated): Liver panel and albumin; blood, urine, CSF cultures/counts

FBN/GI:

- Initiate home feeding
- **Provide breastfeeding mothers with breast pump, kit, and pumping instructions** if prolonged ED stay
- Attempt enteral repletion of hydration (PO or NG)
- IV hydration only if severe dehydration or electrolyte abnormalities



If patient sent to ED:


- **Triage RN:** ESI level 2 (acute)
- **ED RN:**
 - Obtain sample for total and direct serum bilirubin and POCT glucose via heel stick, regardless of need for additional labs or IV access (includes patients w/prior result < 8 hrs old)
 - Place infant on bili blanket STAT

Exchange Transfusion (Appendix B) or BiITool therapy immediately wait for a NICU bed

Hyperbilirubinemia in the Neonate Clinical Pathway – Emergency & Inpatient Management

Initial provider assessment

- Critical clinical history & physical exam are included
 - essential to determine phototherapy and exchange transfusion criteria
- Determine treatment threshold with BiliTool.org or AAP nomograms 2022
- Must also consider if there is a pathological rate of rise $\geq 0.2\text{mg/dL/hour}$
- Appendix C added to support review of etiologies and risk factors




Initial Provider Assessment

Clinical history/physical exam:

- Gestational Age
- Current age in hours
- Mother's blood type (Infant's blood type if mother type O, Rh negative, or antibody +)
- Birth weight and current weight
- Method and frequency of feeding
- Stool and urine output
- Signs/level of dehydration

Hyperbilirubinemia Evaluation for Treatment:

- Consider etiologies and risk factors for neonatal hyperbilirubinemia (Appendix C)
- Determine if there is pathologic rate of rise ($\geq 0.2\text{mg/dL/hour}$ or $> 5\text{mg/dL}$ in 24 hours)
- Determine threshold for phototherapy and exchange transfusion using BiliTool or Phototherapy Nomograms (Appendix A) and Exchange Transfusion Nomograms (Appendix B)



RETURN TO THE BEGINNING

Hyperbilirubinemia in the Neonate Clinical Pathway. – Appendix C: Etiologies and Risk Factors

Etiologies of Hyperbilirubinemia

<p><u>Increased Bilirubin Production</u></p> <ul style="list-style-type: none"> • Hemolytic Disease <ul style="list-style-type: none"> ○ Isoantibodies <ul style="list-style-type: none"> ▪ ABO ▪ Rh ▪ Minor antibodies ○ Enzyme defects <ul style="list-style-type: none"> ▪ Glucose-6-phosphate deficiency ▪ Pyruvate kinase deficiency ○ Structural defects <ul style="list-style-type: none"> ▪ Spherocytosis ▪ Elliptocytosis • Birth trauma <ul style="list-style-type: none"> ○ Scalp hematoma ○ Excessive bruising • Polycythemia 	<p><u>Other or Combined Etiologies</u></p> <ul style="list-style-type: none"> • Family history of inherited hemolytic disorders • Prematurity • Metabolic disorder <ul style="list-style-type: none"> ○ Hypothyroidism ○ Galactosemia • Infection <ul style="list-style-type: none"> ○ Urinary tract infection ○ Sepsis • Breastfeeding (non-breastfeeding/starvation jaundice) • Drugs <ul style="list-style-type: none"> ○ Sulfisoxazole ○ Streptomycin ○ Benzyl alcohol ○ Chloramphenicol
<p><u>Decreased Bilirubin Excretion</u></p> <ul style="list-style-type: none"> • Biliary obstruction <ul style="list-style-type: none"> ○ Biliary atresia ○ Choledochal cyst ○ Dubin-Johnson syndrome ○ Rotor syndrome 	<p><u>Impaired Bilirubin Conjugation</u></p> <ul style="list-style-type: none"> • Gilbert syndrome • Crigler-Najjar syndrome I and II • Human milk jaundice

Risk Factors to Consider

<p><u>Risk Factors for Development of Significant Hyperbilirubinemia for Infants ≥ 35 Weeks Gestation</u></p> <ul style="list-style-type: none"> • Lower gestational age (ie, risk increases with each week < 40 weeks) • Jaundice observed in first 24 hours after birth • Predischarge from birth hospital TcB or TSB close to phototherapy threshold • Phototherapy before birth hospital discharge • Blood group incompatibility <ul style="list-style-type: none"> ○ Positive direct antiglobulin test ○ Other hemolytic disease (G6PD) ○ Elevated ETCO₂ • Parent or sibling requiring phototherapy or exchange transfusion • Family history or genetic ancestry suggestive of inherited red blood cell disorders, including G6PD • Scalp hematoma or significant bruising • Down syndrome • Macrosomic infant of a diabetic mother 	<p><u>Risk Factors for Hemolysis</u></p> <ul style="list-style-type: none"> • Early onset jaundice (within 1st 24 hours after birth) • Requirement for phototherapy or exchange transfusion during the birth hospitalization • Near-threshold bilirubin levels within the first 48 hours after birth (within 2mg/dL of phototherapy threshold) • Rapidly rising TSB levels (increasing by ≥ 0.3 mg/dL per hour in the 1st 24 hours or ≥ 0.2 mg/dL per hour thereafter) • ABO incompatibility, regardless of DAT • Familial or racial or ethnic history of inherited hemolytic disorder
---	---

Adapted from: Kemper, A. R., et al. (2022). Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation. *Pediatrics*, 150(3), e2022058859.



RETURN TO THE BEGINNING





Hyperbilirubinemia in the Neonate Clinical Pathway. – Emergency & Inpatient Management

Initial Laboratory

- Guidance for evaluating patient's risk for hemolysis and appropriate labs to obtain added
- Included clarification for which patients to screen for G6PD
- Clarified additional lab considerations

Laboratory: Consider additional labs as clinically indicated

- **CBC w diff, reticulocyte count, DAT, (if not known), type and screen, peripheral smear** - If mother/baby blood types unknown, early-onset jaundice (first 24 hrs after birth), phototx or exchange transfusion during birth hospitalization, bilirubin levels w/in 2 mg/dL of threshold in 1st 48 hrs of life, rapidly rising TSB levels (increasing by ≥ 0.2 mg/dL per hour), ABO incompatibility regardless of DAT result, family hx inherited hemolytic disorder
- **G6PD** – if clinical concern for hemolysis and DAT negative, or if early onset hyperbili and persistent beyond first week of life, familial or racial or ethnic risk
- **Electrolytes, POCT urine dip for specific gravity** – Obtain if concern for moderate or severe dehydration
- Additional labs considerations (if clinically indicated): Liver panel and albumin; blood, urine, CSF cultures/counts



RETURN TO THE BEGINNING

Hyperbilirubinemia in the Neonate Clinical Pathway. – Emergency Room Management

If meets criteria for discharge from ED

- Critical to provide appropriate post discharge feeding and pumping guidance to caregivers
- Ensure timely post discharge follow up with primary care provider

Discharge with close follow up

- Discharge Instructions:**
- Continue feedings on demand with goal of 10-12 feedings per day. Follow up with PCP 1 day after discharge
 - Continue feeding, supplementing feedings, and pumping as recommended by Primary Care Team

Inclusion criteria: newborns already discharged from birth hospital or who remain in NICU AND are ≤14 days old, born at ≥35 wk gestation, previously suspected/known indirect hyperbilirubinemia with suspected/known need for phototherapy
Exclusion Criteria: >14 days old; <35 wk gestation at birth, suspected sepsis, signs of hyperbilirubinemia neurotoxicity

Determine appropriate admission service (MS Floor vs NICU) based on outpatient bilirubin [Admission Algorithm]:

- If patient sent to ED:
- Triage RN: ESI Level 2 (acute)
 - ED RN:
 - Obtain sample for total and direct serum bilirubin and POCT glucose via heel stick, regardless of need for additional labs or IV access (includes patients w/prior result < 8 hrs old)
 - Place infant on bili blanket STAT

- Signs of Hyperbilirubinemia Neurotoxicity
- Hypertonia
 - Arching
 - Retrocollis
 - Opisthotonos
 - Fever
 - High pitched cry

Initial Provider Assessment

Clinical history/physical exam:

- Gestational Age
- Current age in hours
- Mother's blood type (infant's blood type if mother type O, Rh negative, or antibody +)
- Birth weight and current weight
- Method and frequency of feeding
- Stool and urine output
- Signs/level of dehydration

Hyperbilirubinemia Evaluation for Treatment:


- Consider etiologies and risk factors for neonatal hyperbilirubinemia (Appendix C)
- Determine if there is pathologic rate of rise (≥ 0.2mg/dL/hour or > 5mg/dL in 24 hours)
- Determine threshold for phototherapy and exchange transfusion using BiITool or Phototherapy Nomograms (Appendix A) and Exchange Transfusion Nomograms (Appendix B)

Laboratory: Consider additional labs as clinically indicated

- CBC w diff, reticulocyte count, DAT, (if not known), type and screen, peripheral smear - If mother/baby blood types unknown, early-onset jaundice (first 24 hrs after birth), phototox or exchange transfusion during birth hospitalization, bilirubin levels w/in 2 mg/dL of threshold in 1st 48 hrs of life, rapidly rising TSB levels (increasing by ≥0.2 mg/dL per hour), ABO incompatibility regardless of DAT result, family hx inherited hemolytic disorder
- G6PD - If clinical concern for hemolysis and DAT negative, or if early onset hyperbili and persistent beyond first week of life, familial or racial or ethnic risk
- Electrolytes, POCT urine dip for specific gravity - Obtain if concern for moderate or severe dehydration
- Additional labs considerations (if clinically indicated): Liver panel and albumin; blood, urine, CSF cultures/counts


FBN/GI:

- Facilitate home feeding
- Educate feeding mothers with breast pump, kit, and pumping instructions if prolonged ED stay
- Ensure completion of hydration (PO or NG)
- Address severe dehydration or electrolyte abnormalities



RETURN TO THE BEGINNING





This is the Hyperbilirubinemia in the Neonate Clinical Pathway. – Inpatient Management

Inpatient algorithm also pulls out initial provider assessment, important H&P details, risk factors, and initial laboratory guidance which is the same as the ED content

We will review the additional inpatient management content on the next few slides



RETURN TO THE BEGINNING



Appendix D provides additional tips and tricks for nurses

- Setting up for admission
- Setting up phototherapy
- Where to obtain equipment at CT Children's Hartford campus
- Admitting RN responsibilities



Setting up for Admission:

- **Review Phototherapy Nursing Policy**
- **Gather equipment (location listed in table below)**
- **Set up for Phototherapy**
 - White sheet should be covering all sides of open bassinet, and infant placed on top of sheet
 - Bilirubin blanket should be placed in bassinet and will be beneath infant, overhead lights above
 - Overhead lights slide underneath cot
 - Overhead lights no closer than 30 cm to infant as per manufacturer recommendations
 - Goal dose of phototherapy is $\geq 30 \mu\text{W}/\text{cm}^2/\text{nm}$ – assessed with bili-meter at time of set up and once daily on MS floors

Equipment	Location
Open cot/bassinet	One cot designated for MedSurg units, usually found in back storage hallway (MS7), otherwise call NICU and 5-TEAM will deliver
Isolette (incubator) – only when indicated for critically ill, premature, temperature concerns	NICU
Overhead Phototherapy Lights	Equipment Depot
Bilirubin Blanket	Equipment Depot
Bilirubin Blanket Disposable Pad Covers	MS6 and MS7 Omni
Bilimeter (radiometer)	Equipment Depot
Purple eye shields	MS6 and MS7 Omni
Breast Pump and Supplies	Equipment Depot/ Omni
Milk weight scale	MS Clean Storage Room
White linen	MS Clean Utility/Storage Rooms




RETURN TO THE BEGINNING



Setting up phototherapy

- White sheet to cover bottom and all sides of open cot
- Biliblanket below infant
- Light bank above infant
- Ensure maximum skin exposure to all light surfaces



See **Appendix D: Admitting RN Tips and Tricks**

Phototherapy Set Up:


- Prepare open infant bassinet with white sheet over sides and bottom
- Arrange phototherapy light bank above and bilirubin blanket below infant
- Ensure maximum skin exposure to all light surfaces, cover eyes
- Position light banks at least 10 cm from infant

Phototherapy Management:

- Initiate continuous intensive phototherapy ($\geq 30 \mu\text{W}/\text{cm}^2/\text{nm}$) upon admission. For Connecticut Children's employees, please refer to **Connecticut Children's Phototherapy Policy**
 - Record start and stop times in phototherapy flowsheet
- Measure phototherapy light level with bili-meter at initiation and daily. Document in flowsheet.

Duration of Phototherapy:

- Infant may be out for feedings for a total of 30 mins in a 2 hour time period
 - Use bilirubin blanket during feedings
- Discontinue phototherapy when TSB decreased by at least 2 mg/dL below the threshold at the **initiation** of phototherapy (*Consider longer phototherapy if risk factors for rebound hyperbili*)



Hyperbilirubinemia in the Neonate Clinical Pathway. –Inpatient Management

Phototherapy


- Defined intensive phototherapy dose: $\geq 30 \mu\text{W}/\text{cm}^2/\text{nm}$
- Tips on setting up, maintaining, and monitoring intensive phototherapy added
- Added guidance to consider discontinuing phototherapy when TSB decreased by at least 2 mg/dL below threshold at the initiation of phototherapy

CLINICAL PATHWAY: Hyperbilirubinemia Inpatient Management

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

Management of phototherapy

- Goal irradiance dose is $\geq 30 \mu\text{W}/\text{cm}^2/\text{nm}$
- Recording start and stop times of treatment on phototherapy flow sheet is essential
- Measuring phototherapy irradiance/light level with bili-meter ensures proper light dose



CONTACTS: JILL HERRING, APRN | MARY LUSSIER, RN, IBCLC | ILANA WAYNIK, MD | KRISTIN WELCH, MD

LAST UPDATED: 02/27/23

©2019 Connecticut Children’s Medical Center. All rights reserved.




Initial Laboratory

- Guidance for evaluating patient's risk for hemolysis and appropriate labs to obtain added
- Included clarification for which patients to screen for G6PD
- Clarified additional lab considerations



- TSB** – Obtain if ED or outpatient total serum bilirubin obtained > 6 hours from admission (or sooner if ≤ 2 points of exchange transfusion nomogram line)
- Direct Bilirubin** – Obtain if direct serum bili not done in ED or patient is a direct admit to PHM
- CBC w diff, reticulocyte count, DAT, (if not known), type and screen, peripheral smear** - If mother/baby blood types unknown, early-onset jaundice (first 24 hrs after birth), phototx or exchange transfusion during birth hospitalization, bilirubin levels w/in 2 mg/dL of threshold in 1st 48 hrs of life, rapidly rising TSB levels (increasing by ≥ 0.2 mg/dL per hour), ABO incompatibility regardless of DAT result, family hx inherited hemolytic disorder
- G6PD** – If clinical concern for hemolysis and DAT negative, or if early onset hyperbilirubinemia and persistent beyond first week of life, familial or racial or ethnic risk
- Electrolytes, POCT urine dip for specific gravity** – Obtain if concern for moderate or severe dehydration:
- Additional Lab Considerations (if clinically indicated):** liver panel, albumin and blood, urine, CSF cultures/counts




CLINICAL PATHWAY: Hyperbilirubinemia Inpatient Management

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.

TSB monitoring DURING phototherapy

- Ensure effective decline in TSB with treatment
- Distance for exchange tx line determines next TSB timing
- Once TSB is declining, AND > 2 points from exchange threshold can repeat ~ every 6-12 hours



TSB monitoring DURING phototherapy:

- If admission TSB within ≤ 2 points of threshold line on exchange nomogram, repeat TSB in 2 hrs
- If admission TSB > 2 points of threshold line on exchange nomogram, repeat TSB in 4-6 hrs and then if TSB declining, every 8-12 hrs

CONTACTS: JILL HERRING, APRN | MARY LUSSIER, RN, IBCLC | ILANA WAYNIK, MD | KRISTIN WELCH, MD


LAST UPDATED: 02/27/23

©2019 Connecticut Children's Medical Center. All rights reserved.



CLINICAL PATHWAY: Hyperbilirubinemia Inpatient Management

THIS PATHWAY
SERVES AS A GUIDE
AND DOES NOT
REPLACE CLINICAL
JUDGMENT.



TSB monitoring AFTER phototherapy

- For most patients a repeat TSB 1 day after stopping phototherapy is appropriate
- Can be obtained as outpatient or inpatient, as clinically indicated
- Updated criteria for when to consider TSB 6-12 hours after phototherapy discontinued

CONTACTS: JILL HERRING, APRN | MARY LUSSIER, RN, IBCLC | ILANA WAYNIK, MD | KRISTIN WELCH, MD

LAST UPDATED: 02/27/23

©2019 Connecticut Children's Medical Center. All rights reserved.



Nutrition

- Nutrition optimization is essential for hyperbili treatment
- Goal feeding volumes based on age have been added to guide supplementation
- Lactation support for breastfeeding patients is integral to feeding optimization
- Goal breastfeedings is at least 10-12 time per day (minimum every 2-3 hours)


- Initiate home feeding
- Assess for **signs of suboptimal intake (Appendix D page 2)**
- Assess for dehydration
- Attempt enteral repletion (PO, NGT PRN)
- IVFs only for: clinical or biochemical signs of dehydration and unable to replete enterally
- Vitamin D3 400 IU daily

Breastfed Infants

- Order Lactation Consult
- **Admitting RN:**
 - Provide breast pump, instructions, pumping schedule
 - Provide/review Kid's Health education on Jaundice and Breastfeeding
 - Complete Epic task/order for "Education: mother's milk expression, milk weights, supplementation"
- **Feeds:**
 - Feed on demand, minimum q 2-3 hrs, 10-12 feeds in 24 hrs
 - Supplement post feeds at breast if:
 - Suboptimal feedings volumes at breast based on milk weights
- **Minimum total feed volume by age**
 - 48-96 hour old: 30 mL/feed
 - 96 hours – 7 days old: 45 mL/feed
 - 7 – 14 days old: 60 mL/feed
- **Weights:**
 - Milk weights before and after all feeds
 - Daily morning weights

Formula Fed Infants

- Infant formula ad lib on demand
- Resume pre-hospital formula after discharge



RETURN TO THE BEGINNING



Importance of Enteral Feeding



- Enteral feeding allows optimal excretion of bilirubin via bile and intestinal route
- Consider Nasogastric feedings if there are feeding difficulties
- Inadequate feeding results in increased intestinal resorption of bilirubin and higher unconjugated bilirubin levels (“increased enterohepatic circulation”)
- Meconium is a reservoir of unconjugated bilirubin
 - Poor passage of stool = more absorption of unconjugated bilirubin

RN Responsibilities Upon Admission:

Appendix D page 9 also provides additional tips and tricks for nurses

- Admitting RN responsibilities
 1. Tips for phototherapy and labs
 2. Breastfeeding and nutritional support to provide upon arrival (pump and pump kit, instructions for pumping, milk weight scale, provide feeding log)
 3. Guidance for how to assess for suboptimal intake



1. Phototherapy and Bilirubin Labs Tips

- Obtain Total Serum Bilirubin if > 2 hours since last and then start phototherapy
- Start continuous intensive phototherapy ($\geq 30 \mu\text{W}/\text{cm}^2/\text{nm}$) with lights above and bilirubin blanket beneath patient - when infant arrives
- Adjusting the phototherapy dose
 - Measure the irradiance (light intensity) of the phototherapy with the Bili-meter
 - Loosen the height adjustment clamp on the stand and adjust the height of the phototherapy unit to achieve an irradiance goal of at least $\geq 30 \mu\text{W}/\text{cm}^2/\text{nm}$.
 - Minimum clearance between the lower edge of the phototherapy lamp and the patient is at least 30 cm per manufacturer guidelines.
 - Infant is only wearing a diaper to maximize skin to light exposure
 - Purple eye shields in place on infant
 - Light intensity level should be checked at initiation of phototherapy and at least once a day with bili-meter. **Goal intensity is $\geq 30 \mu\text{W}/\text{cm}^2/\text{nm}$.** (blanket meter is tan, overhead light meter is blue)
- Document on "Phototherapy Flowsheet": start, stop, and any phototherapy documentation items in this flow sheet

2. Breastfeeding and Nutrition Support Upon Patient Arrival

- **Breast pump and pumping kit**
 - Instruct breastfeeding mother on **use of the pump** and to **pump after all feedings**
 - Complete/document completion of this order/task by clicking "done" in Epic
- **Milk weight scale**
 - Instruct mother on how to weigh the baby pre and post feedings
 - **Milk weights** are to be done for **all feedings** at breast and recorded on flow sheet
- **Provide mother a breastfeeding log (Appendix E)**
- **Document** that breast pump, pumping kit, pumping instructions, milk weight scale, and feeding log were given to mother
- Print off "**Breastfeeding and Jaundice**" patient hand out from **Kids Health** and review with mother
- **Assess feedings** at breast for **suboptimal intake**
 - Goal total feed volume by age
 - 48-96 hour old: 30 mL/feed
 - 96 hours – 7 days old: 45 mL/feed
 - 7 – 14 days old: 60 mL/feed
 - Ineffective latch and/or suck
 - Sleepy and difficulty to wake for feedings
 - Delayed milk supply
 - Laboratory abnormalities (hypoglycemia)
 - Uric acid crystals in urine
 - < 4 stools on day 4 or meconium stools on day 5



RETURN TO THE BEGINNING



Measuring feedings at Breast with Milk Weight Scale

Milk Weight Scale

- Use before and after feedings at breast
 - 1 gram = 1 mL breast milk
- Assists in assessing supply
- Help determine potential need to supplement
- Every feeding at breast & recorded on flow sheet




Use of IV Fluids



- Most infants with hyperbilirubinemia do not require IV fluids
- IVFs may decrease infant's desire to take oral feedings, and thus prolong jaundice
- Consider use of nasogastric tube in place of IVFs, if unable to take adequate PO intake, as clinically appropriate
- Consider IVF if evidence of moderate dehydration:
 - Hemodynamic instability
 - Moderate to severe electrolyte abnormalities
 - Unable to correct these factors enterally

Discharge Criteria:

- Infant medically stable with an acceptable TSB level
- For most patients TSB level at least 2 pts below the threshold at the initiation of phototherapy is acceptable (consider longer phototx for patients with rebound risk factors)
- Oral intake and weight are appropriate
- Appropriate follow up services in place: PCP, lactation, VNA as needed



Discharge Criteria:


Acceptable TSB level; taking adequate intake as defined by multidisciplinary team; absence of excessive weight loss; adequate follow up plan with PCP; confirm breast pump available for home for breastfeeding infants; follow up appointments in place (PCP with in 1-2 days after discharge, lactation consultant if indicated); VNA referral for weight checks and feeding assessment to alternate with PCP follow up if indicated

Discharge Instructions:

Continue feedings on demand with goal of 10-12 feedings per day; follow up with PCP 1 day after discharge; continue feeding, supplementing feedings, and pumping as recommended by multidisciplinary team including lactation consultant

Discharge Instructions:

- Ensure family is given a feeding plan to support continued feeding optimization
 - Includes guidance for supplementing and when it would be appropriate to stop supplementing
 - Goal feeding 10-12 times per day
- PCP follow up 1 day after discharge



Discharge Criteria:

Acceptable TSB level; taking adequate intake as defined by multidisciplinary team; absence of excessive weight loss; adequate follow up plan with PCP; confirm breast pump available for home for breastfeeding infants; follow appointments in place (PCP within 1-2 days after discharge, lactation consultant if indicated); VNA referral for weight checks and feeding assessment to alternate with PCP follow up if indicated

Discharge Instructions:

Continue feedings on demand with goal of 10-12 feedings per day; follow up with PCP 1 day after discharge; continue feeding, supplementing feedings, and pumping as recommended by multidisciplinary team including lactation consultant

Review of Key Points



- Clear admission and treatment criteria
- Phototherapy and Exchange Transfusion nomograms updated in line with APP 2022 revision
- Optimization of feeding and nutrition is critical
- Appropriate set up and dose of phototherapy are essential
- Appropriate lab evaluation for at risk populations guides phototherapy duration and need for closer rebound testing, as well as other long term monitoring needs
- Close follow up with PCP after discharge is a must

Quality Metrics



- % Patients with pathway order set
- % Patients with breastfeeding education performed
- % Patients with lactation consult obtained ≤ 24 hours of arrival
- % Patients with phototherapy start time documented
- Average time (minutes) from arrival to phototherapy start time
- % Patients with phototherapy intensity > 30
- % Families reporting breastfeeding continued at 1 week
- % Families reporting breastfeeding continued at 1 month
- % Families unable to be reached at 1 week
- % Families unable to be reached at 1 month
- ALOS (days), IP/OBS

Pathway Contacts



- Jill Herring, APRN
 - Pediatric Hospital Medicine
- Ilana Waynik, MD
 - Pediatric Hospital Medicine
- Mary Lussier, RN, IBCLC
 - Lactation
- Kristin Welch, MD
 - Pediatric Emergency Medicine

References



- Kemper, A. R., et al. (2022). [Clinical Practice Guideline Revision: Management of Hyperbilirubinemia in the Newborn Infant 35 or More Weeks of Gestation](#). *Pediatrics*, 150(3), e2022058859.
- American Academy of Pediatrics Subcommittee on Hyperbilirubinemia (2004). [Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation](#). *Pediatrics*, 114(1), 297–316.
- Flaherman VJ, Maisels MJ, and the Academy of Breastfeeding Medicine. [ABM Clinical Protocol # 22: Guidelines for Management of Jaundice in the Breastfeeding Infant 35 weeks or More of Gestation – Revised 2017](#). *Breastfeeding Medicine*. 2017;12(5): 250-57.
- Kellams, A, Harrel, C, Omage, et al, and the Academy of Breastfeeding Medicine. [ABM Clinical Protocol # 3: Supplementary Feedings in Healthy Term Breastfed Neonate, Revised 2017](#). *Breastfeeding Medicine*. 2017;12(3): 1-11.
- Maisels JM, Bhutani VK, Bogen D, Newman TB, Stark AR, Watchko JF. [Hyperbilirubinemia in the Newborn Infant 35 Weeks or More Gestation: An Update with Clarifications](#). *Pediatrics*. 2009 October;124(4):1193-98.

Thank You!



About Connecticut Children's Clinical Pathways Program

The Clinical Pathways Program at Connecticut Children's aims to improve the quality of care our patients receive, across both ambulatory and acute care settings. We have implemented a standardized process for clinical pathway development and maintenance to ensure meaningful improvements to patient care as well as systematic continual improvement. Development of a clinical pathway includes a multidisciplinary team, which may include doctors, advanced practitioners, nurses, pharmacists, other specialists, and even patients/families. Each clinical pathway has a flow algorithm, an educational module for end-user education, associated order set(s) in the electronic medical record, and quality metrics that are evaluated regularly to measure the pathway's effectiveness. Additionally, clinical pathways are reviewed annually and updated to ensure alignment with the most up to date evidence. These pathways serve as a guide for providers and do not replace clinical judgment.